JP2022512647A - 抗黄色ブドウ球菌(Staphylococcus aureus)抗体の組み合わせ - Google Patents

抗黄色ブドウ球菌(Staphylococcus aureus)抗体の組み合わせ Download PDF

Info

Publication number
JP2022512647A
JP2022512647A JP2021519612A JP2021519612A JP2022512647A JP 2022512647 A JP2022512647 A JP 2022512647A JP 2021519612 A JP2021519612 A JP 2021519612A JP 2021519612 A JP2021519612 A JP 2021519612A JP 2022512647 A JP2022512647 A JP 2022512647A
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
aureus
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021519612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512647A5 (cg-RX-API-DMAC7.html
Inventor
トゥカチク,クリスティン
セルマン,ブレット
ドゥ,チュン
ダムシュローダー,メリッサ
コーエン,テイラー
Original Assignee
メディミューン,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン,エルエルシー filed Critical メディミューン,エルエルシー
Publication of JP2022512647A publication Critical patent/JP2022512647A/ja
Publication of JP2022512647A5 publication Critical patent/JP2022512647A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021519612A 2018-10-09 2019-10-08 抗黄色ブドウ球菌(Staphylococcus aureus)抗体の組み合わせ Ceased JP2022512647A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862743490P 2018-10-09 2018-10-09
US62/743,490 2018-10-09
US201962833297P 2019-04-12 2019-04-12
US62/833,297 2019-04-12
PCT/US2019/055143 WO2020076789A2 (en) 2018-10-09 2019-10-08 Combinations of anti-staphylococcus aureus antibodies

Publications (2)

Publication Number Publication Date
JP2022512647A true JP2022512647A (ja) 2022-02-07
JP2022512647A5 JP2022512647A5 (cg-RX-API-DMAC7.html) 2022-10-18

Family

ID=70051346

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021519612A Ceased JP2022512647A (ja) 2018-10-09 2019-10-08 抗黄色ブドウ球菌(Staphylococcus aureus)抗体の組み合わせ

Country Status (11)

Country Link
US (2) US11168133B2 (cg-RX-API-DMAC7.html)
EP (1) EP3864041A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022512647A (cg-RX-API-DMAC7.html)
KR (1) KR20210072057A (cg-RX-API-DMAC7.html)
CN (1) CN113164602A (cg-RX-API-DMAC7.html)
AU (1) AU2019357983A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006622A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115633A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004173A (cg-RX-API-DMAC7.html)
TW (1) TW202035443A (cg-RX-API-DMAC7.html)
WO (1) WO2020076789A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512646A (ja) * 2018-10-09 2022-02-07 メディミューン,エルエルシー スタフィロコッカス・アウレウス(Staphylococcus aureus)ロイコトキシンに対して向けられた抗体

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
JP7682795B2 (ja) 2019-03-13 2025-05-26 メディミューン,エルエルシー コロニー形成患者における黄色ブドウ球菌(Staphylococcus aureus)感染症の低減
KR20230049584A (ko) * 2020-05-07 2023-04-13 플라이언트 테라퓨틱스, 인크. 아미노산 화합물을 사용한 호흡기 질환의 치료
CN117771379B (zh) * 2023-10-25 2024-08-30 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合
CN121537524B (zh) * 2026-01-20 2026-04-28 江西省人民医院 一种mda5人源化单克隆抗体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
ATE458006T1 (de) 2003-05-14 2010-03-15 Kenta Biotech Ag Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
CN1324049C (zh) 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP2009539979A (ja) 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
KR20110044991A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TNF-α 길항제 다-표적 결합 단백질
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
CN102387814A (zh) 2009-01-29 2012-03-21 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
LT3444268T (lt) 2010-05-05 2022-04-11 New York University Staphylococcus aureus leukocidinai, terapinės kompozicijos ir jų panaudojimo būdai
RS58190B2 (sr) 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
ES2912267T3 (es) 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
CN105873946A (zh) 2013-10-17 2016-08-17 阿尔萨尼斯生物科学有限责任公司 交叉反应性金黄色葡萄球菌抗体序列
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン,エルエルシー 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤
WO2017075188A2 (en) * 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. Vol.61 Iss.8, JPN6023037087, 2017, pages 00629 - 17, ISSN: 0005150125 *
血管腫・血管奇形治療マニュアル, JPN6023037085, 2012, pages 9 - 15, ISSN: 0005150124 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512646A (ja) * 2018-10-09 2022-02-07 メディミューン,エルエルシー スタフィロコッカス・アウレウス(Staphylococcus aureus)ロイコトキシンに対して向けられた抗体
JP7459075B2 (ja) 2018-10-09 2024-04-01 メディミューン,エルエルシー スタフィロコッカス・アウレウス(Staphylococcus aureus)ロイコトキシンに対して向けられた抗体

Also Published As

Publication number Publication date
EP3864041A2 (en) 2021-08-18
US20200109189A1 (en) 2020-04-09
CN113164602A (zh) 2021-07-23
WO2020076789A2 (en) 2020-04-16
US11168133B2 (en) 2021-11-09
KR20210072057A (ko) 2021-06-16
AU2019357983A1 (en) 2021-05-27
MX2021004173A (es) 2021-09-08
CA3115633A1 (en) 2020-04-16
US20220089699A1 (en) 2022-03-24
TW202035443A (zh) 2020-10-01
WO2020076789A3 (en) 2020-10-22
BR112021006622A2 (pt) 2021-07-20

Similar Documents

Publication Publication Date Title
US11168133B2 (en) Combinations of anti-Staphylococcus aureus antibodies
US10730934B2 (en) Antibodies to S. aureus surface determinants
US11970527B2 (en) Antibody directed against S. aureus clumping factor A (ClfA)
JP6473746B2 (ja) 交差反応性黄色ブドウ球菌抗体配列
KR20150031298A (ko) 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
JP7459075B2 (ja) スタフィロコッカス・アウレウス(Staphylococcus aureus)ロイコトキシンに対して向けられた抗体
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
US11530256B2 (en) Antibody specific to alpha-toxin of Staphylococcal aureus and uses thereof
CN107614517B (zh) 抗感染疾病的抗体
RU2804815C2 (ru) Комбинации антител к staphylococcus aureus
RU2805969C2 (ru) Антитела, направленные против лейкотоксинов staphylococcus aureus
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus
CN117771379A (zh) 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合
HK40025295A (en) Antibodies to s. aureus surface determinants
HK1215054B (en) Antibodies to s. aureus surface determinants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240730